Rational use of antibiotics in acute uncomplicated cystitis: A pharmaco-epidemiological study

Journal of Chemotherapy

Volumn 17, Issue 2, 2005, Pages 184-188

  Arone, F ^a   Morrone, L A ^a   Bagetta, D ^a   Florio, L ^b   Lista, M R ^b   Bagetta, G ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Territorial Pharmaceutical Area of Paola (CS)   (Italy)

Author keywords

Acute cystitis; Amoxicillin; Antimicrobial resistance; Community acquired urinary tract infections; Cystitis; Lower respiratory tract infection; Uncomplicated cystitis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; CEFTIBUTEN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; LOMEFLOXACIN; NETILMICIN; QUINOLONE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMMUNICABLE DISEASE; CONTROLLED STUDY; CYSTITIS; DRUG COST; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; ITALY; MALE; PHYSICIAN; URINARY TRACT INFECTION;

EID: 19544385056     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.2.184     Document Type: Article

References (23)

1. Project Sphere-Office Health. Study on the consumption of the medicines in Italy. IMS; 2003.
2. Signalings From The World Health Organization. The progress of the medicine threatened by the medicine-resistance. Pharmaco-Economy, Year V, (2001); n. 1: 5-6.
3. Bassetti D. Criterions of choice of the antibacterial chemotherapy. In: Bassetti D, eds. Anti-infectious Chemother. and their rational employment 2001; 18: 359-360.
4. Graham Neil MH. Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract. PharmacoEconomics 1994; 5 (suppl. 2): 1-10.
5. Chambers HF, Sande MA. Chemotherapy of infectious diseases. In: Hardman JG, Limbird LE, Gilman AG, eds. The Pharmacological Bases of Therapeutics. 9th ed. Tx, Usa. McGraw-Hill. 1997; 43: 1009-1018.
6. IMS Health.
7. Appel GB. Aminoglycoside nephrotoxicity: studies of the sites of nephron damage, The Aminoglycosides: Microbiology, Clinical use, and Toxicity, 1982; 269-282.
8. Jawetz E. Antibiotic aminoglycosides and polymyxin. In: Katzung BG, ed. General Pharmacology and Clinic. Padova, Italy. Piccin. 1997; 45: 758-765.
9. Capri S. The Pharmaco-Economy: methods of analysis. In: Clementi F, Fumagalli G, eds. Economy and Normative of the Medicine, 1998; 5: 53-67.
10. L'Informatore Farmaceutico, Italian directory of medicines and manufacturers, OEMF, 2003; part I: 207-210.
11. Gerald L, Mandell and Petri WA, Jr. Penicillins, cephalosporins and other beta-lactam antibiotics. In: Hardman JG, Limbird LE, Gilman AG, eds. The Pharmacological Bases of Therapeutics. 9th ed. Tx, Usa. McGraw-Hill. 1997; 46: 1058-1059.
12. Falkow S, Mekalanos J. Entero-bacterias and Vibrio. In: Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, eds. Microbiology. 4th ed. Bologna, Italy. Zanichelli. 1998; 27: 577-605.
13. Bassetti D. Reasoned therapy of the Principal Infectious Syndromes. In: Bassetti D, ed. Anti-infectious Chemotherapy and their rational employment. 7th ed. 2001; 19: 385-389.
14. La Placa M. Synoptics Tables of Clinical Microbiology. In: La Placa M, ed. Principles of Medical Microbiology. Esculapio. Bologna, Italy. 2000; 714-719.
15. Bassetti D. Beta-lactam. In: Bassetti D, ed. Anti-infectious Chemotherapy and their rational employment, 2001; 5: 86-120.
16. Mandell G L, Petri WA, Jr. Sulphamidics, trimethoprim-sulfamethoxazole, quinolones and medicines for the infections of the tract urinary. In: Hardman JG, Limbird LE, Gilman AG, eds. The Pharmacological Bases of Therapeutics. 9th ed. Tx, USA. McGraw-Hill. 1997; 44: 1031-1044.
17. Bassetti D. Various antibiotics. In: Bassetti D, ed. Anti-infectious Chemotherapy and their rational employment, 2001; 15: 299-301.
18. Hooper D C. The future of the quinolones, APUA (Alliance for the Prudent use of Antibiotics) Newsletter 2001, 19 (3).
19. Avom J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000; 133:128-135.
20. Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. Washington DC: US Government Printing Office. Publication OTA-H-629; 1995.
21. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonos aeruginosa, Arch Intern Med 1999; 159: 1127-1132.
22. White VLC, Moore-Gillon L. Resources implication of patients with multidrug resistant tuberculosis, Thorax, 2000; 55: 962-963.
23. L'Informatore Farmaceutico, Italian directory of medicines and manufacturers, OEMF, 2003; part III: 1581-1706.